NCT00848029View on ClinicalTrials.gov

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Pre-pandemic Influenza Vaccine
Interventions
BIOLOGICAL

Monovalent inactivated influenza vaccine

Two doses of monovalent inactivated influenza adjuvanted vaccine

Trial Locations (1)

500 03

Vaccination and Travel Medicine Centre, Hradec Králové

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY